-- Motixafortide effectively mobilized sufficient hematopoietic stem cells (HSCs) in patients with sickle cell disease and beta-thalassemia enabling accelerated access to gene therapies -- 73% (11 of ...

Motixafortide alone and in combination with natalizumab can support the collection of the large number of stem cells required by gene therapies for sickle cell disease within a single apheresis cycle ...

Stem cell mobilization and transplantation represent pivotal advances in the management of multiple myeloma. This therapeutic approach involves stimulating the release of haematopoietic stem cells ...

REDWOOD CITY, Calif.--(BUSINESS WIRE)-- Exicure, Inc. (Nasdaq: XCUR), a clinical-stage biotechnology company developing therapeutics for hematologic diseases, today announced it has completed patient ...

Motixafortide alone and in combination with natalizumab (VLA-4 inhibitor) led to robust hematopoietic stem cell (HSC) mobilization predicting 16.9 million and 19.6 million cells/kg collected in a ...